Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Conference

Rhea-AI Summary

Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced its participation in the virtual H.C. Wainwright BioConnect Conference from January 10-13, 2022. The company will present on January 10, with availability for 90 days. Foghorn focuses on developing novel therapies aimed at genetically determined dependencies within the chromatin regulatory system, particularly in oncology. Its Gene Traffic Control Platform supports the identification of potential drug targets, with multiple candidates currently being investigated in clinical studies.

CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Foghorn^® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Foghorn will present at the H.C. Wainwright BioConnect Conference which is being held virtually on January 10^th through the 13^th, 2022. With an initial focus in oncology, Foghorn’s Gene Traffic Control Platform and resulting broad pipeline has the potential to transform the lives of people suffering from a wide spectrum of diseases.

H.C. Wainwright BioConnect Conference
Format: Presentation
Date: Monday, January 10, 2022 and will be available for 90 days
All company presentations will be available on-demand beginning at 7:00am ET
Please find a link to the presentation here.

A webcast of the presentation can also be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com.

About Foghorn Therapeutics
Foghorn^® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control^® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology with two currently being investigated in clinical studies.

Contact:

Ben Strain, Foghorn Therapeutics (Media and Investors)
bstrain@foghorntx.com

Gregory Kelley, Ogilvy (Media)
gregory.kelley@ogilvy.com

Hans Vitzthum, LifeSci Advisors (Investors)
hans@lifesciadvisors.com

FAQ

When is Foghorn Therapeutics presenting at the H.C. Wainwright BioConnect Conference?

Foghorn Therapeutics will present on January 10, 2022.

What is the focus of Foghorn Therapeutics?

Foghorn Therapeutics focuses on developing therapies for genetically determined dependencies within the chromatin regulatory system, primarily in oncology.

How long will Foghorn's presentation be available after the conference?

Foghorn's presentation will be available for 90 days after the conference.

Where can I access Foghorn's conference presentation?

Foghorn's presentation can be accessed on their website under 'Events & Presentations' or via a provided link.

What platform does Foghorn use for drug discovery?

Foghorn uses its Gene Traffic Control Platform for discovering and developing new drug targets.